Reduction in 3-month confirmed disability progression in secondary progressive multiple sclerosis
FRIDAY, March 23, 2018 (HealthDay News) — For patients with secondary progressive multiple sclerosis, the selective sphingosine 1-phosphate (S1P) receptor1,5 modulator, siponimod, is associated with reduced relative risk of confirmed disability progression, according to a study published online March 22 in The Lancet.
Ludwig Kappos, M.D., from the University of Basel in Switzerland, and colleagues conducted a phase 3 trial at 292 hospital clinics and specialized multiple sclerosis centers in 31 countries. Patients with SPMS and an Expanded Disability Status Scale score of 3.0 to 6.5 were randomized in a 2:1 ratio to once-daily oral siponimod 2 mg or placebo. A total of 1,645 patients were included in the analyses: 1,099 to the siponimod group and 546 to the placebo group; 903 and 424 patients completed the study, respectively.
The researchers found that 26 and 32 percent of patients receiving siponimod and placebo had three-month confirmed disability progression events (hazard ratio, 0.79; relative risk reduction, 21 percent). Adverse events occurred in 89 and 82 percent of patients taking siponimod and placebo, respectively; serious adverse events were reported for 18 and 15 percent, respectively.
“Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS,” the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Novartis, which manufactures siponimod and funded the study.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2018 HealthDay. All rights reserved.
